-+ 0.00%
-+ 0.00%
-+ 0.00%

Chemomab amends domestication merger terms ahead of planned Scipher deal

PUBT·09/30/2026 20:08:32
Listen to the news
Chemomab amends domestication merger terms ahead of planned Scipher deal
  • Amendment set a formula-based exchange ratio for Chemomab’s redomiciling into the U.S. ahead of its merger with Scipher.
  • Revision aims to fix the number of parent-company shares issued so the combined company has 10,000,000 shares outstanding at closing.
  • Terms keep the deal’s economics unchanged, including consideration and the relative ownership split between Chemomab and Scipher holders.
  • Transaction remains targeted for the fourth quarter of 2026, with the combined company expected to trade on Nasdaq under “SCIP.”
  • Post-close, the parent plans to rename itself Scipher Medicine Corporation, led by CEO Reginald Seeto; Chemomab CEO Adi Mor joins the board.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Chemomab Therapeutics Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001178913-26-004676), on September 30, 2026, and is solely responsible for the information contained therein.